The company has created a new nucleic acid synthesis technology that improves the quality and speed of synthesis, offering increased accuracy over existing Phosphoramidite synthesis technology. Camena Bioscience produces genes for a range of biotechnology customers, including those in the pharmaceutical, agriculture, and diagnostics sectors. Its multi-enzymatic technology provides access to long and complex gene sequences, which are normally difficult to produce. Founded in 2016 and headquartered in Cambridge, UK, Camena Bioscience serves companies across the world, enabling researchers and the synthetic biology revolution with its technology.